Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery

Oncogene volume 21, pages 5791–5796 (2002)Cite this article

Abstract

A recent large multi-centre study convincingly confirmed previous observations that the SYT-SSX1 fusion type, compared to SYT-SSX2, of synovial sarcoma is associated with a worse clinical outcome. Apart from the clinical impact, this fact also suggests (1) that the SYT-SSX fusion gene may influence molecular mechanisms involved in tumour growth and progression; and (2) that the SYT-SSX1 fusion type has a stronger influence on these mechanisms than SYT-SSX2. The nature of the underlying mechanisms is, however, still unknown. In this study we made use of the SYT-SSX1 vs SYT-SSX2 concept to investigate whether major, tumour relevant, and growth regulatory proteins (e.g. cyclins and cyclin-dependent kinases) may be involved. Using Western blotting analysis on 74 fresh, fusion variant-typed, tumour samples from localized synovial sarcoma, we found a significant correlation between SYT-SSX1 and high expression of cyclin A (P=0.003) and D1 (P=0.025). Our data suggest that SYT-SSX may influence the cell cycle machinery, and that the more aggressive phenotype of the SYT-SSX1 variant is due to an accelerated tumour cell proliferation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Adams JM, Cory S . 1998 Science 281: 1322–1326

  • Bukholm IR, Bukholm G, Nesland JM . 2001 Int. J. Cancer 93: 283–287

  • Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, Gusterson BA, Cooper CS . 1994 Nat. Genet. 7: 502–508

  • de Leeuw B, Baltmans M, Olde Weghuis D, Geurts van Kessel A . 1995 Hum. Mol. Genet. 4: 1097–1099

  • dos Santos NR, de Bruijn DR, van Kessel AG . 2001 Genes Chromos. Cancer 30: 1–14

  • Evan GI, Vousden KH . 2001 Nature 411: 342–348

  • Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T . 1999 Int. J. Cancer 84: 225–233

  • Hunter T, Pines J . 1994 Cell 79: 573–582

  • Huuhtanen RL, Blomqvist CP, Bohling TO, Wiklund TA, Tukiainen EJ, Virolainen M, Tribukait B, Andersson LC . 1999 Cancer Res. 59: 2885–2990

  • Inagaki H, Nagasaka T, Otsuka T, Sugiura E, Nakashima N, Eimoto T . 2000 Mod. Pathol. 13: 482–488

  • Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M . 1998 N. Engl. J. Med. 338: 153–160

  • Kim SH, Lewis JJ, Brennan MF, Woodruff JM, Dudas M, Cordon-Cardo C . 1998 Clin. Cancer Res. 4: 2377–2382

  • Ladanyi M . 2001 Oncogene 20: 5755–5762

  • Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O . 2002 Cancer Res. 62: 135–140

  • Mancuso T, Mezzelani A, Riva C, Fabbri A, Dal Bo L, Sampietro G, Perego P, Casali P, Zunino F, Sozzi G, Pierotti MA, Pilotti S . 2000 Lab. Invest. 80: 805–813

  • Mishina T, Dosaka-Akita H, Hommura F, Nishi M, Kojima T, Ogura S, Shimizu M, Katoh H, Kawakami Y . 2000 Clin. Cancer Res. 6: 11–16

  • Nielsen NH, Arnerlov C, Emdin SO, Landberg G . 1996 Br. J. Cancer 74: 874–880

  • Nilsson G, Skytting B, Xie Y, Brodin B, Perfekt R, Mandahl N, Lundeberg J, Uhlen M, Larsson O . 1999 Cancer Res. 59: 3180–3184

  • Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF, Sherr CJ . 1993 Genes Dev. 7: 1559–1571

  • Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Inoue M, Yano M, Kimura Y, Yamamoto M, Monden M . 1998 Int. J. Oncol. 13: 455–460

  • Sherr CJ . 1995 Trends Biochem. Sci. 20: 187–190

  • Sherr CJ . 1996 Science 274: 1672–1677

  • Sherr CJ . 2000 Cancer Res. 60: 3689–3695

  • Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlen M, Larsson O . 1999 J. Natl. Cancer Inst. 91: 974–975

  • Thaete C, Brett D, Monaghan P, Whitehouse S, Rennie G, Rayner E, Cooper CS, Goodwin G . 1999 Hum. Mol. Genet. 8: 585–591

  • Turc-Carel C, Dal Cin P, Limon J, Rao U, Li FP, Corson JM, Zimmerman R, Parry DM, Cowan JM, Sandberg AA . 1987 Proc. Natl. Acad. Sci. USA 84: 1981–1985

  • Xie Y, Skytting B, Nilsson G, Gasbarri A, Haslam K, Bartolazzi A, Brodin B, Mandahl N, Larsson O . 2002 Cancer Res. 62: (in press)

Download references

Acknowledgements

This project was supported by grants from the Swedish Cancer Society, the Cancer Society in Stockholm, the Swedish Children Cancer Society and the Karolinska Institute.

Author information

Authors and Affiliations

  1. Department of Oncology and Pathology, CCK R8: 04, Karolinska Hospital, Stockholm, Sweden

    Yuntao Xie & Olle Larsson

  2. Department of Oncology, Zhongnan Hospital, Wuhan University, Wuhan, PR China

    Yuntao Xie

  3. Department of Orthopedics, Stockholm Soder Hospital, Stockholm, Sweden

    Bjorn Skytting

  4. Department of Orthopedics, Karolinska Hospital, Stockholm, Sweden

    Gunnar Nilsson

  5. Royal Orthopaedic Hospital, Northfield, Birmingham, UK

    Robert J Grimer & Chas D Mangham

  6. Department of Pathology, the Royal Marsden NHS Trust, London, UK

    Cyril Fisher

  7. Molecular Cytogenetics Team, Institute of Cancer Research, Sutton, UK

    Janet Shipley

  8. Department of Pathology, nstitute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

    Bodil Bjerkehagen

  9. Department of Tumour Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

    Ola Myklebost

Authors
  1. Yuntao Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bjorn Skytting
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gunnar Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert J Grimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chas D Mangham
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cyril Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Janet Shipley
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bodil Bjerkehagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ola Myklebost
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Olle Larsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olle Larsson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xie, Y., Skytting, B., Nilsson, G. et al. The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery. Oncogene 21, 5791–5796 (2002). https://doi.org/10.1038/sj.onc.1205700

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205700

Keywords

This article is cited by

Search

Advanced search

Quick links